New eye drug PRO-169 takes on lucentis in major trial
NCT ID NCT05217680
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new eye medication called PRO-169 against a standard drug (ranibizumab) for people with diabetic macular edema, a condition that causes vision loss in people with diabetes. About 509 adults with diabetes took part, receiving injections into the eye over one year. The goal was to see if PRO-169 works as well as the standard treatment at improving eyesight.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
SalaUno Salud, S.A.P.I. de C.V.
Mexico City, 06030, Mexico
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new eye injection preserve vision in south asians with diabetes?
- Could a biosimilar eye injection offer a new way to treat diabetic macular edema?
- Can a steroid implant boost the effect of standard eye injections for hard-to-treat diabetic macular edema?
- Eye injection aims to tame leading causes of blindness
- New eye drug aims to restore vision in Diabetes-Related swelling
- New eye drug aims to restore vision in Diabetes-Related swelling